Literature DB >> 10869170

Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid.

S L Parikh1, G Xiao, P J Tonge.   

Abstract

Structural and genetic studies indicate that the antibacterial compound triclosan, an additive in many personal care products, is an inhibitor of EnvM, the enoyl reductase from Escherichia coli. Here we show that triclosan specifically inhibits InhA, the enoyl reductase from Mycobacterium tuberculosis and a target for the antitubercular drug isoniazid. Binding of triclosan to wild-type InhA is uncompetitive with respect to both NADH and trans-2-dodecenoyl-CoA, with K(i)' values of 0.22+/-0.02 and 0.21+/-0.01 microM, respectively. Replacement of Y158, the catalytic tyrosine residue, with Phe, reduces the affinity of triclosan for the enzyme and results in noncompetitive inhibition, with K(i) and K(i)' values of 36+/-5 and 47+/-5 microM, respectively. Consequently, the Y158 hydroxyl group is important for triclosan binding, suggesting that triclosan binds in similar ways to both InhA and EnvM. In addition, the M161V and A124V InhA mutants, which result in resistance of Mycobacterium smegmatis to triclosan, show significantly reduced affinity for triclosan. Inhibition of M161V is noncompetitive with K(i)' = 4.3+/-0.5 microM and K(i) = 4.4+/-0.9 microM, while inhibition of A124V is uncompetitive with K(i)' = 0. 81 +/- 0.11 microM. These data support the hypothesis that the mycobacterial enoyl reductases are targets for triclosan. The M161V and A124V enzymes are also much less sensitive to isoniazid compared to the wild-type enzyme, indicating that triclosan can stimulate the emergence of isoniazid-resistant enoyl reductases. In contrast, I47T and I21V, two InhA mutations that occur in isoniazid-resistant clinical isolates of M. tuberculosis, show unimpaired inhibition by triclosan, with uncompetitive inhibition constants (K(i)') of 0.18+/-0.01 and 0.12+/- 0.01 microM, respectively. The latter result indicates that InhA inhibitors targeted at the enoyl substrate binding site may be effective against existing isoniazid-resistant strains of M. tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10869170     DOI: 10.1021/bi0008940

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  59 in total

1.  Location and orientation of Triclosan in phospholipid model membranes.

Authors:  Jaime Guillén; Angela Bernabeu; Stuart Shapiro; José Villalaín
Journal:  Eur Biophys J       Date:  2004-01-09       Impact factor: 1.733

Review 2.  Targeting InhA, the FASII enoyl-ACP reductase: SAR studies on novel inhibitor scaffolds.

Authors:  Pan Pan; Peter J Tonge
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

Review 3.  Targeting the formation of the cell wall core of M. tuberculosis.

Authors:  Clifton E Barry; Dean C Crick; Michael R McNeil
Journal:  Infect Disord Drug Targets       Date:  2007-06

4.  Evaluating the Contribution of Transition-State Destabilization to Changes in the Residence Time of Triazole-Based InhA Inhibitors.

Authors:  Lauren A Spagnuolo; Sandra Eltschkner; Weixuan Yu; Fereidoon Daryaee; Shabnam Davoodi; Susan E Knudson; Eleanor K H Allen; Jonathan Merino; Annica Pschibul; Ben Moree; Neil Thivalapill; James J Truglio; Joshua Salafsky; Richard A Slayden; Caroline Kisker; Peter J Tonge
Journal:  J Am Chem Soc       Date:  2017-02-22       Impact factor: 15.419

5.  Direct inhibitors of InhA are active against Mycobacterium tuberculosis.

Authors:  Ujjini H Manjunatha; Srinivasa P S Rao; Ravinder Reddy Kondreddi; Christian G Noble; Luis R Camacho; Bee H Tan; Seow H Ng; Pearly Shuyi Ng; Ng L Ma; Suresh B Lakshminarayana; Maxime Herve; Susan W Barnes; Weixuan Yu; Kelli Kuhen; Francesca Blasco; David Beer; John R Walker; Peter J Tonge; Richard Glynne; Paul W Smith; Thierry T Diagana
Journal:  Sci Transl Med       Date:  2015-01-07       Impact factor: 17.956

6.  Structure of acyl carrier protein bound to FabI, the FASII enoyl reductase from Escherichia coli.

Authors:  Salma Rafi; Polina Novichenok; Subramaniapillai Kolappan; Christopher F Stratton; Richa Rawat; Caroline Kisker; Carlos Simmerling; Peter J Tonge
Journal:  J Biol Chem       Date:  2006-09-29       Impact factor: 5.157

7.  Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors.

Authors:  Christopher W am Ende; Susan E Knudson; Nina Liu; James Childs; Todd J Sullivan; Melissa Boyne; Hua Xu; Yelizaveta Gegina; Dennis L Knudson; Francis Johnson; Charles A Peloquin; Richard A Slayden; Peter J Tonge
Journal:  Bioorg Med Chem Lett       Date:  2008-04-18       Impact factor: 2.823

8.  Elucidating the structural basis of diphenyl ether derivatives as highly potent enoyl-ACP reductase inhibitors through molecular dynamics simulations and 3D-QSAR study.

Authors:  Pharit Kamsri; Auradee Punkvang; Patchareenart Saparpakorn; Supa Hannongbua; Stephan Irle; Pornpan Pungpo
Journal:  J Mol Model       Date:  2014-06-17       Impact factor: 1.810

9.  Mechanism and inhibition of the FabV enoyl-ACP reductase from Burkholderia mallei.

Authors:  Hao Lu; Peter J Tonge
Journal:  Biochemistry       Date:  2010-02-16       Impact factor: 3.162

Review 10.  'FAS't inhibition of malaria.

Authors:  Avadhesha Surolia; T N C Ramya; V Ramya; Namita Surolia
Journal:  Biochem J       Date:  2004-11-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.